Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker

Background: Elevated plasmatic lactate dehydrogenase (LDH) levels are associated with worse prognosis in various malignancies, including metastatic breast cancer (MBC). Nevertheless, no data are available on the prognostic role of LDH as a dynamic biomarker during first-line treatment in unselected...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Pelizzari, Giacomo, Basile, Debora, Zago, Silvia, Lisanti, Camilla, Bartoletti, Michele, Bortot, Lucia, Vitale, Maria Grazia, Fanotto, Valentina, Barban, Serena, Cinausero, Marika, Bonotto, Marta, Gerratana, Lorenzo, Mansutti, Mauro, Curcio, Francesco, Fasola, Gianpiero, Minisini, Alessandro Marco, Puglisi, Fabio
Format: Artigo
Language:Inglês
Published: MDPI 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770929/
https://ncbi.nlm.nih.gov/pubmed/31450641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11091243
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items